Skip to main content

Table 1 Clinical characteristics of DLBCL patients in the GDPH and TCGA datasets (n = 124)

From: Tumor mutation burden estimated by a 69-gene-panel is associated with overall survival in patients with diffuse large B-cell lymphoma

Variables GDPH dataset, n (%)a TCGA dataset, n (%)a P value
Number 87 37  
Gender 0.528
 Female 44 (50.6) 21 (56.8)  
 Male 43 (49.4) 16 (43.2)  
Age, years 0.638
 Younger than 60 51 (58.6) 20 (54.1)  
 Older than 60 36 (41.4) 17 (45.9)  
Immunophenotype NA
 GCB 24 (27.6)  
 Non-GCB 46 (52.9)  
 Unclassified 2 (2.3)  
 Unknown 15 (17.2)  
Serum LDH level  < 0.001
 Normal 31 (35.6) 12 (32.4)  
 Elevated 56 (64.4) 12 (32.4)  
 Unknown 0 (0.0) 13 (35.1)  
Extranodal involvement  < 0.001
 0–1 47 (54.0) 17 (45.9)  
 More than 1 40 (46.0) 10 (27.0)  
 Unknown 0 (0.0) 10 (27.0)  
ECOG PS NA
 0–1 66 (75.9)  
 2–4 21 (24.1)  
Ann Arbor stage  < 0.001
 I/II 33 (37.9) 21 (56.8)  
 III/IV 54 (62.1) 11 (29.7)  
 Unknown 0 (0.0) 5 (13.5)  
IPI score NA
 0–2 46 (52.9)  
 3–5 41 (47.1)  
DHL/DEL NA
 Yes 30 (34.5)  
 No 57 (65.5)  
HBsAg NA
 Positive 17 (19.5)  
 Negative 70 (80.5)  
Anti-HBc NA
 Positive 18 (20.7)  
 Negative 69 (79.3)  
HBV-DNA NA
 Positive 10 (11.5)  
 Negative 77 (88.5)  
Treatment NA
 R-CHOP 74 (85.1)  
 BFM-90 1 (1.1)  
 Rituximab + Lenalidomide 7 (8.0)  
 Radiation 0 (0) 6 (16.2)  
 Unknown 5 (5.7) 1 (2.7)  
  1. aDue to rounding, not all percentages total 100%
  2. anti-HBc antibody to hepatitis B core antigen, BFM-90 Berlin–Frankfurt–Munster-90 regimen, DHL/DEL double-hit and double-expressor lymphomas, ECOG PS Eastern Cooperative Oncology Group performance status, GDPH Guangdong Provincial People’s Hospital, GCB germinal center B cells, HBsAg hepatitis B surface antigen, HBV-DNA hepatitis B virus DNA, IPI international prognostic index, LDH lactate dehydrogenase, NA not available, R-CHOP rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone